每经AI快讯，英诺特（SH 688253，收盘价：31.87元）8月28日晚间发布公告称，公司第二届第十次董 事会会议于2025年8月27日以现场结合通讯方式召开。会议审议了《关于公司2025年半年度报告及其摘 要的议案》等文件。 截至发稿，英诺特市值为43亿元。 每经头条（nbdtoutiao）——申请超2万份，已开出41家，加盟海底捞，你要准备多少钱？1000万元不算 多，真实"账单"公布 （记者 王可然） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 2024年1至12月份，英诺特的营业收入构成为：体外诊断行业占比100.0%。 ...

Company Summary - The company, Tuojing Life (SZ 300642), announced a share buyback of approximately 210,000 shares, representing 0.13% of its total share capital, executed through a centralized bidding transaction on August 28, 2025 [1] - The highest price for the repurchased shares was 29.34 CNY per share, while the lowest price was 27.3 CNY per share, with a total expenditure of approximately 5.91 million CNY [1] - As of the report date, Tuojing Life's market capitalization stands at 4.5 billion CNY [1] Industry Summary - For the fiscal year 2024, Tuojing Life's revenue is entirely derived from the in vitro diagnostics industry, accounting for 100% of its revenue [1]

证券日报网讯万孚生物（300482）8月28日在互动平台回答投资者提问时表示，公司深耕体外诊断领域 30年，万孚生物持续响应社会对肝炎防治的健康需求，联动胶体金、免疫荧光、化学发光等平台上市了 超10款肝病检测产品，覆盖甲肝、乙肝、丙肝、戊肝及肝癌等，可为肝炎防治提供全面检测方案。随 着"星火计划"在广东及全国推进，相关创新成果将在更大范围内发挥作用，为更多地区肝炎筛查和防治 提供有力支持。 ...

Core Viewpoint - The company, Shuoshi Biological, announced voluntary salary reductions for its executives in response to challenging market conditions and declining performance, reflecting a commitment to long-term development and cost efficiency [1][3]. Executive Salary Reduction - Eight executives, including the honorary chairman and the chairman, will see salary cuts ranging from 5% to 50%, with the honorary chairman's salary reduced by 50% and the chairman's by 50% as well [1]. - Five of the seven executives who voluntarily reduced their salaries had annual salaries exceeding 1 million yuan in 2024, with specific figures including 2.0643 million yuan for the honorary chairman and 2.4399 million yuan for the chairman [1]. Financial Performance - The company's revenue showed significant growth from 17.40 billion yuan in 2020 to 55.35 billion yuan in 2022, but it faced a drastic decline in 2023 with revenue dropping to 4.03 billion yuan and a net loss of 374 million yuan [3]. - For the first half of 2025, the company reported a revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit of 39.926 million yuan, down 86.35% compared to the previous year [3]. Dividend Distribution - Despite the decline in performance and executive salary cuts, the company approved a cash dividend of 3.4 yuan per 10 shares, totaling 285 million yuan, indicating a desire to reward investors while maintaining a healthy cash flow [4]. - The company emphasized its commitment to balancing dividends with future research and development investments, stating that technology innovation remains a core driver [4]. Market Position - As of August 28, the company's stock price was 63.92 yuan per share, with a total market capitalization of 5.316 billion yuan, reflecting its current market standing [5].

Core Viewpoint - The management team of Shuoshi Biology (688399) voluntarily proposed salary reductions ranging from 5% to 50% to support the company's operational cost optimization and enhance management efficiency in response to challenging global economic conditions and industry environment [2][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [3][4]. - Other executives, including Liu Zhonghua (director and deputy general manager), Hu Yuanyuan (director, deputy general manager, and board secretary), and Zhou Guohui (deputy general manager), will see a 40% reduction [3][4]. - The financial director, Meng Yuanyuan, and employee supervisors, Jia Zhaoqiang and Gu Lina, will have their salaries reduced by 10% and 5%, respectively [3][4]. Company Performance - Shuoshi Biology reported a significant decline in performance, with a net profit loss of 374 million yuan in 2023, a 120.45% year-on-year decrease [5][6]. - The company's revenue for the first half of 2025 was 176 million yuan, a decrease of 1.05% compared to the previous year, with a net profit of 3.99 million yuan, down 86.35% year-on-year [6][7]. - The company has faced continuous pressure on its operations, with two consecutive years of net profit losses [5][6]. Market Context - The decline in performance is attributed to the pressure on product prices due to the nationwide implementation of centralized procurement in the in vitro diagnostic industry, along with changes in tax rates and reduced government subsidies [7][8]. - As of August 27, 2023, Shuoshi Biology's stock price was 63.08 yuan per share, with a total market capitalization of 5.3 billion yuan [9].

Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), announced that several executives voluntarily proposed salary reductions in response to ongoing industry challenges and to support long-term development [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2]. - Other executives, including Liu Zhonghua (40% reduction), Hu Yuanyuan (40% reduction), and Zhou Guohui (40% reduction), will also see significant salary cuts, while the financial director and employee supervisors will have reductions of 10% and 5% respectively [2][3]. Executive Compensation Context - Among the seven executives who proposed salary cuts, five had annual salaries exceeding 1 million yuan in 2024, with Fang Yongsheng earning 2.0643 million yuan and Wang Guoqiang earning 2.4399 million yuan [3][4]. - The company previously had several executives with annual salaries exceeding 10 million yuan in 2021 and 2022 [4]. Financial Performance - The company has faced continuous operational pressure, with a reported revenue of 176 million yuan in the first half of 2025, a year-on-year decrease of 1.05%, and a net profit of 3.9926 million yuan, down 86.35% [7]. - Shuoshi Biotechnology has recorded net losses for two consecutive years, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively [7]. Dividend Distribution - Despite the decline in performance and executive salary reductions, the company plans to distribute a cash dividend of 2.85 billion yuan for the first half of 2025, reflecting a commitment to return value to shareholders [9]. - The company reported that as of June 30, the undistributed profits exceeded 2.4 billion yuan, allowing for the dividend distribution while maintaining a stable cash flow [9].

Core Viewpoint - Jiangsu Shuoshi Biotechnology Co., Ltd. announced voluntary salary reductions for its executives and board members to support operational cost optimization and enhance competitiveness amid challenging global economic conditions [1][3]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua and Hu Tongyuan, will see a 40% reduction, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [2][3]. Company Performance Context - Shuoshi Biotechnology experienced significant revenue growth during the pandemic, with revenues soaring from 289 million yuan in 2019 to 5.535 billion yuan in 2022, but faced a dramatic decline in 2023 with revenues dropping to 403 million yuan, a 92.72% decrease year-over-year [4][5]. - The company reported a net loss of 374 million yuan in 2023, marking a 120.45% decline compared to the previous year [4][5]. Future Strategies - The company aims to continue optimizing operations and enhancing market competitiveness through cost reduction and efficiency improvement measures [3][4].

Core Viewpoint - The company, Shuoshi Biological (688399.SH), announced voluntary salary reductions for several executives, including a 50% cut for the honorary chairman and the chairman/general manager, in response to ongoing financial pressures and to demonstrate solidarity during challenging market conditions [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman/general manager, Wang Guoqiang, will have their salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua (director and deputy general manager), Hu Tongyuan (director, deputy general manager, and board secretary), and Zhou Guohui (deputy general manager), will see a 40% salary reduction [2][3]. - The financial director, Meng Yuanyuan, and employee supervisors, Jia Zhaoqiang and Gu Lina, will have their salaries reduced by 10% and 5%, respectively [2][3]. Financial Performance - The company has faced declining financial performance, with a reported revenue of 176 million yuan in the first half of 2025, a decrease of 1.05% year-on-year, and a net profit of 3.99 million yuan, down 86.35% [7]. - The company has experienced net losses for two consecutive years, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively, and corresponding net profits of -374 million yuan and -2 million yuan [7]. Dividend Distribution - Despite the salary cuts and declining performance, the company plans to distribute a cash dividend of 34.00 yuan per 10 shares, totaling 285 million yuan, reflecting a commitment to return value to shareholders [9]. - As of June 30, the parent company had over 2.4 billion yuan in undistributed profits, allowing for this dividend distribution while maintaining a stable cash flow [9].

每经AI快讯，博拓生物（SH 688767，收盘价：39.8元）8月28日晚间发布公告称，公司第四届第二次董 事会会议于2025年8月27日在公司会议室以现场结合通讯方式召开。会议审议了《关于2025年半年度报 告及其摘要的议案》等文件。 截至发稿，博拓生物市值为59亿元。 （记者 贾运可） 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ 2024年1至12月份，博拓生物的营业收入构成为：体外诊断试纸占比92.91%，其他业务占比7.09%。 ...

格隆汇8月28日丨博拓生物(688767.SH)公布2025年半年度报告，报告期内，公司实现营业收入2.03亿 元，同比下降23.91%；归属于上市公司股东的净利润1240.24万元，同比下降82.82%；归属于上市公司 股东的扣除非经常性损益的净利润683.48万元，同比下降90.25%；基本每股收益0.07元。 ...